Targeting PD-I/PD-LI in lung cancer: Current perspectives

Lung Cancer: Targets and Therapy

Volumn 6, Issue , 2015, Pages 55-70

  González Cao, María ^a   Karachaliou, Niki ^a   Viteri, Santiago ^a   Morales Espinosa, Daniela ^a   Teixidó, Cristina ^b   Ruiz, Jesús Sánchez ^c   Molina Vila, Miquel Ángel ^b   Santarpia, Mariacarmela ^d   Rosell, Rafael ^a,b,e,f  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b Pangaea Biotech SL   (Spain)

^c Structural Biology and Biocomputing Programme   (Spain)

^d UNIVERSITY OF MESSINA   (Italy)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f Fundacion Molecular Oncology Research   (Spain)

Author keywords

Cancer; Checkpoint inhibitors; Immunoncology; Immunotherapy

Indexed keywords

AMP 224; ANTINEOPLASTIC AGENT; AVELUMAB; BMS 936559; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; ERLOTINIB; IPILIMUMAB; MEDI 0680; MITOGEN ACTIVATED PROTEIN KINASE; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; NONHUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; REVIEW; SMALL CELL LUNG CANCER; SMOKING; SOLID TUMOR; SQUAMOUS CELL LUNG CARCINOMA;

EID: 84942319348     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/LCTT.S55176     Document Type: Review

References (127)

1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl J Med. 2010; 363(8):711-723.
2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. NEngl JMed. 2012;366(26): 2443-2454.
3. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-3175.
4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immu- noediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-998.
5. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-258.
6. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992;71(7):1065-1068.
7. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71(7):1093-1102.
8. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993; 259(5093):368-370.
9. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-113.
10. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860-867.
11. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964.
12. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306.
13. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203-213.
14. Gros A, Robbins PF, Yao X, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246-2259.
15. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174(3):561-569.
16. Salvi S, Fontana V, Boccardo S, et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer immunolImmunother. 2012;61(9):1463-1472.
17. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity. 1997;7(4):445-450.
18. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1(5):405-413.
19. Kearney ER, Walunas TL, Karr RW, et al. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. JImmunol. 1995;155(3):1032-1036.
20. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2): 459-465.
21. Krummel MF, Sullivan TJ, Allison JP. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol. 1996;8(4):519-523.
22. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541-547.
23. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270(5238):985-988.
24. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA- 4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity. 1997;7(6):885-895.
25. Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503-513.
26. Gandhi MK, Lambley E, Duraiswamy J, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood. 2006;108(7):2280-2289.
27. Zhu C, Anderson AC, Schubart A, et al. The TIM-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005; 6(12):1245-1252.
28. Sabatos CA, Chakravarti S, Cha E, et al. Interaction of TIM-3 and TIM-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4(11):1102-1110.
29. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK,Anderson AC. Targeting TIM-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10): 2187-2194.
30. Gao X, Zhu Y, Li G, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 2012;7(2):e30676.
31. Zhuang X, Zhang X, Xia X, et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol. 2012;137(6):978-985.
32. Zhou P, Shaffer DR, Alvarez Arias DA, et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature. 2014; 506(7486):52-57.
33. Le Mercier I, Chen W, Lines JL, et al. VISTA regulates the development of protective antitumor immunity. Cancer Res. 2014;74(7): 1933-1944.
34. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014; 94(1):107-116.
35. Chen YY, Wang LB, Zhu HL, et al. Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin MedSci J. 2013;28(3):147-151.
36. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori. 2012;98(6):751-755.
37. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
38. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800.
39. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111-122.
40. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-smallcell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535-546.
41. Karwacz K, Bricogne C, MacDonald D, et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med. 2011;3(10):581-592.
42. Freire J, Ajona D, de Biurrun G, et al. Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment. Neoplasia. 2013;15(8):913-924.
43. O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5(12):2024-2036.
44. Li CW, Xia W, Huo L, et al. Epithelial-mesenchymal transition induced by TNF-a requires NF-KB-mediated transcriptional upregulation of Twist1. Cancer Res. 2012;72(5):1290-1300.
45. So T, Takenoyama M, Mizukami M, et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res. 2005;65(13):5945-5952.
46. Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5(5): 585-590.
47. Srivastava MK, Andersson A, Zhu L, et al. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy. 2012;4(3): 291-304.
48. Brahmer J, Horn L, Antonia S, et al. Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2013.
49. Gettinger S, Chow LQ, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2014;90(5):S34-S35.
50. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257-265.
51. Antonia SJ, Brahmer JR, Gettinger S, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2014;90(5):S2.
52. Garon E, Balmanoukian A, Hamid O, et al. Preliminary safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). Presented at: Annual Congress of the American Society of Clinical Oncology (ASCO); 2014.
53. Garon EB, Gandhi L, Rizvi N, et al. Antitumor activity of pembroli- zumab (pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Ann Oncol. 2014; 25 (Supplement 5):v1-v41.
54. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti- PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
55. Khleif S, Lutzky J, Segal N, et al. MEDI4736, an anti-PD-Ll antibody with modified Fc domain: preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors. Presented at: European Cancer Congress 2013; 2013.
56. Lutzky J, Antonia SJ, Blake-Haskins A, et al. A phase 1 study of MEDI4736, an anti-PD-Ll antibody, in patients with advanced solid tumors. J Clin Oncol. 2014;32:5s(Suppl; abstr 3001).
57. Segal NH, Antonia S, Brahmer J, et al. Preliminary data from a multiarm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol. 2014;32:5s(Suppl; abstr 3002).
58. Spigel D, Gettinger S, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2013;31.
59. Soria JC, Cruz C, Bahleda R, et al. Clinical activity, safety, and biomarkers of a PD-L1 blockade in non-small cell lung cancer (NSCLC9: additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1)). Presented at: European Cancer Congress 2013;2013.
60. Gandhi L, Balmanoukian A, Hui R, et al. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): antitumor activity and association with tumor PD-L1 expression. Presented at: Annual Congress of the American Association for Cancer Research 2014; 2014.
61. Gettinger SN, Shepherd FA, Antonia SJ, et al. First-line nivolumab (anti- PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol. 2014;32:5s(Suppl; abstr 8024).
62. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567.
63. Brahmer JR, Horn L, Gandhi L, et al. Nivolumab (anti-PD-1, BMS- 936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. JClin Oncol. 2014;32:5s(Suppl; abstr 8112).
64. Brahmer JR, Rizvi NA, Lutzky J, et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin Oncol. 2014;32:5s(Suppl; abstr 8021).
65. Garon E, Balmanoukian A, Hamid O, et al. Preliminary clinical safety and activity of MK-3475 mono-therapy for the treatment of previously treated patients with non-small cell lung cancer. lASLC 15th World Conference on Lung Cancer. 2013 Abstract MO18.02.
66. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19): 5064-5074.
67. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-571.
68. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199.
69. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999;91(14):1194-1210.
70. Hellmann MD, Creelan BC, Woo K, et al. Smoking history and response to nivolumab in patients with advanced NSCLCs. Ann Oncol. 2014;25(Supplement 4):IV426-IV470.
71. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046-2054.
72. Xu C, Fillmore CM, Koyama S, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell. 2014;25(5):590-604.
73. Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol. 2013;8(6):803-805.
74. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease- small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75-83.
75. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127-137.
76. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):116-200.
77. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355-1363.
78. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717-1725.
79. Winograd R, Byrne KT, Evans RA, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res. 2015;3(4):399-411.
80. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcyRs, leading to antitumor efficacy. Immunol Cell Biol. 2014;92(6): 475-480.
81. Feder-Mengus C, Wyler S, Hudolin T, et al. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur J Cancer. 2008;44(15):2266-2275.
82. Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP- expressing carcinoma-associated fibroblasts synergizes with anti-PD- L1 immunotherapy in pancreatic cancer. Proc Natl Aca^ Sci U S A. 2013;110(50):20212-20217.
83. Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057-5069.
84. Hasmim M, Noman MZ, Messai Y, et al. Cutting edge: hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-p1. J Immunol. 2013;191(12): 5802-5806.
85. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. Epub February 9, 2015.
86. Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917-927.
87. Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of TIM-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. JExp Med. 2010;207(10): 2175-2186.
88. Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res. 2013;19(18):4917-4924.
89. Fourcade J, Sun Z, Pagliano O, et al. PD-1 and TIM-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. Cancer Res. 2014;74(4):1045-1055.
90. Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of TIM-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117(17):4501-4510.
91. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM-3 antibody promotes T cell IFN-y-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71(10): 3540-3551.
92. Mittal D, Young A, Stannard K, et al. Antimetastatic eJfects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014;74(14): 3652-3658.
93. lannone R, Miele L, Maiolino P, Pinto A, Morello S. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res. 2014;4(2):172-181.
94. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N E^ngl J Med. 2013;369(2):122-133.
95. Antonia S, Gettinger S, Chow LQ, et al. Nivolumab and ipilimumab in first-line NSCLC: interim phase 1 results. Presented at: Annual Congress of the American Society of Clinical Oncology (ASCO); 2014.
96. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225-1231.
97. Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013;19(3):598-609.
98. Atefi M, Avramis E, Lassen A, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Cli^ Cancer Res. 2014;20(13):3446-3457.
99. D’Incecco A, Andreozzi M, Ludovini V, et al. PD-L1 and PD-1 expression in molecularly selected non-small-cell lung cancer (NSCLC) patients. JThorac Oncol. 2014;9(Supplement 9):S7-S52.
100. Ait-Tahar K, Barnardo MC, Pulford K. CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer Res. 2007;67(5):1898-1901.
101. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immu- nostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11(3): 215-233.
102. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10(6):717-728.
103. Zheng Y, de la Cruz CC, Sayles LC, et al. A rare population of CD24(+) ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell. 2013;24(1):59-74.
104. Rizvi N, Chow LQ, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J Clin Oncol. 2014;32:5s(Suppl; abstr 8022).
105. Lou Y, Diao L, Byers LA, et al. Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophe- notype in non-small cell lung cancer: implications for immunotherapy biomarkers. J Clin Oncol. 2014;32:5s(Suppl; abstr 3018).
106. Mathieu J, Zhang Z, Zhou W, et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 2011;71(13):4640-4652.
107. Hasmim M, Noman MZ, Lauriol J, et al. Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells. J Immunol. 2011;187(8):4031-4039.
108. Roselli M, Fernando RI, Guadagni F, et al. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res. 2012;18(14):3868-3879.
109. Hu Y, Mintz A, Shah SR, Quinones-Hinojosa A, Hsu W. The FGFR/ MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival. Carcinogenesis. 2014;35(7):1491-1499.
110. Yuan Z, Syrkin G, Adem A, et al. Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-a leads to synergistic antitumor activity. Cancer Gene Ther. 2013;20(1):46-56.
111. Knights AJ, Fucikova J, Pasam A, Koernig S, Cebon J. Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy. Cancer Immunol Immunother. 2013;62(2): 321-335.
112. Gettinger SN, Horn L, Gandhi L, et al. Long-term survival, clinical activity, and safety of nivolumab (anti-PD-1; BMS-936558, ONO- 4538) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Int JRadiat Oncol Biol Phys. 2014;90(5):S34.
113. Ramalingam SS, Mazieres J, Planchard D, et al. Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;90(5):1266-1267.
114. Rizvi NA, Shepherd FA, Antonia SJ, et al. First-Line monotherapy with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status. Int J Radiat Oncol Biol Phys. 2014;90(5):S31.
115. Rizvi NA, Garon EB, Patnaik A, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32:5s(Suppl; abstr 8007).
116. Brahmer J, Balmanoukian A, Goldberg S, et al. Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 2014;2(Suppl 3):179.
117. Zatloukal P, Heo DS, Park K, et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2009;27:15s(Suppl; abstr 8071).
118. Daud A, Hamid O, Ribas A, et al. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma: correlation of tumor PD-L1 expression with outcome. Presented at: AACR Annual Meeting 2014.
119. Kefford R, Ribas A, Hamid O, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;32:5s(Suppl; abstr 3005).
120. Seiwert TY, Burtness B, Weiss J, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J Clin Oncol. 2014;32:5s(Suppl; abstr 6011).
121. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311-4318.
122. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial. J Clin Oncol. 2015;33(13):1430-1437.
123. Grosso J, Horak CE, Inzunza D, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol. 2013;31(Suppl; abstr 3016).
124. Hodi FS, Sznol M, Kluger HM, et al. Long-term survival of ipili- mumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol. 2014;32:5s(Suppl; abstr 9002).
125. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4): 320-330.
126. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558-562.
127. Hamid O, Sosman JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol. 2013;31(Suppl; abstr 9010).